Swiss drugs firm Roche has offered to buy all outstanding shares in its US partner Genentech for $43.7bn(Ј22bn).
Roche - which makes the antiviral drug Tamiflu - acquired a majority stake in Genentech in 1990 and currently owns 55.9% of all outstanding shares.
It has offered $89 per share to buy up the remaining stake, a 8.8% premium to Genentech's Friday closing share price.
Meanwhile Roche's first-half net profit fell 2% to 5.73bn Swiss francs ($5.59 bn; Ј2.8bn), slightly above forecasts
Group sales increased by 10% to 22bn Swiss US authorities probe UBS over tax ...
Ireland's Mixed Signals on Lisbon Treaty Vote Causes Concern ...
Swiss reject SVP citizenship plan ...
Swiss vote on citizenship curbs ...
Single anti-flu drug 'not enough' ... francs, with the firm saying that double-digit growth of key products outweighed lower sales of Tamiflu.
Roche expects a high single-digit sales increase this year.
It also says that if Genentech shareholders approve Roche's approach then the move will deliver annual pre-tax savings of $750 to $850m.
Franz Humer, chairman of the board of Roche, said: "Combining the strengths of Roche and Genentech will create significant value and result in benefits for patients, employees and shareholders."
(BBC)
<< Back